Product Information
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 is a generic product labeled by Slate Run Pharmaceuticals LLC, priced at $1.0198 per EA under NDC 70436001504. Its NADAC has been published 35 times since Feb 4, 2026.
FDA first approved this application on May 14, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5
olmesartan medoxomil and amlodipine besylate and hydrochlorothiazideStrength
5; 12.5; 40 mg/1; mg/1; mg/1
Manufacturer
Slate Run Pharmaceuticals LLCNDC
70436001504
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA210718FDA Approved
5/14/2025
TE Code
AB
On Market Since
5/15/2025
Pharmacological Classes
Price Statistics
The NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 has been published 35 times since Feb 4, 2026, and over the history we have for it it has declined 22.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0198 per EA |
|---|---|
| All-time high | $1.3200 (Feb 11, 2026) |
| All-time low | $1.0198 (Sep 23, 2026) |
| 52-week high | $1.3200 |
| 52-week low | $1.0198 |
| Median price | $1.1508 |
| Average price | $1.1626 |
| Largest weekly change | -10.0% (Feb 18, 2026) |
| Weeks tracked | 35 |
| Tracking since | Feb 4, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Slate Run Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5?
The current National Average Drug Acquisition Cost (NADAC) for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5, manufactured by Slate Run Pharmaceuticals LLC, is $1.0198 per EA (NDC 70436001504), effective Sep 30, 2026.
How has the price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 changed over time?
Over the history we have for it, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 has declined 22.7%. It has been tracked across 35 weekly CMS publications since Feb 4, 2026.
What are the highest and lowest recorded NADAC prices for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5?
Since Feb 4, 2026, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 has ranged from a low of $1.0198 (Sep 23, 2026) to a high of $1.3200 (Feb 11, 2026), with a median of $1.1508 per EA.
Are there cheaper alternatives to OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5?
No other NADAC-published product currently shares the active ingredient and strength of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5?
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-12.5 (NDC 70436001504) is labeled by Slate Run Pharmaceuticals LLC, and CMS classifies it as a generic product.